Marshall Wace LLP Buys Shares of 89,472 Astrana Health, Inc. (NASDAQ:ASTH)

Marshall Wace LLP bought a new position in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 89,472 shares of the company's stock, valued at approximately $2,821,000. Marshall Wace LLP owned about 0.16% of Astrana Health as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Barclays PLC grew its stake in Astrana Health by 3.4% in the 4th quarter. Barclays PLC now owns 79,543 shares of the company's stock valued at $2,507,000 after purchasing an additional 2,627 shares during the period. Renaissance Technologies LLC increased its holdings in Astrana Health by 217.6% during the fourth quarter. Renaissance Technologies LLC now owns 217,900 shares of the company's stock worth $6,870,000 after buying an additional 149,300 shares during the last quarter. Invesco Ltd. raised its position in Astrana Health by 6.9% in the fourth quarter. Invesco Ltd. now owns 258,520 shares of the company's stock worth $8,151,000 after acquiring an additional 16,717 shares during the period. Envestnet Asset Management Inc. boosted its stake in Astrana Health by 19.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,124 shares of the company's stock valued at $225,000 after acquiring an additional 1,184 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB bought a new position in shares of Astrana Health during the 4th quarter valued at approximately $2,522,000. 52.77% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Stifel Nicolaus lowered their price target on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Truist Financial dropped their price target on Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. Robert W. Baird decreased their price objective on Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Bank of America dropped their price objective on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Finally, Barclays began coverage on shares of Astrana Health in a research report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 target price for the company. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $53.29.

Astrana Health Price Performance

Shares of ASTH stock traded up $0.49 during trading hours on Thursday, reaching $31.66. The stock had a trading volume of 120,132 shares, compared to its average volume of 277,885. The stock's fifty day simple moving average is $30.79 and its 200 day simple moving average is $37.78. The firm has a market capitalization of $1.59 billion, a PE ratio of 24.34, a PEG ratio of 1.37 and a beta of 1.04. Astrana Health, Inc. has a 12 month low of $23.12 and a 12 month high of $63.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). The firm had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. On average, equities research analysts predict that Astrana Health, Inc. will post 1.15 EPS for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.